Suppr超能文献

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver DiseasesNovember 1-5, 2013 • Washington DCSpecial Reporting on:• Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection• Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection• Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations• All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV• Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in DifficuIt-to-Treat HCV Infection• Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNAPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDWeill Cornell Medical CollegeNew York, New York.

出版信息

Gastroenterol Hepatol (N Y). 2014 Jan;10(1 Suppl 1):1-19.

PMID:25337060
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4201083/
Abstract
摘要

相似文献

1
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver DiseasesNovember 1-5, 2013 • Washington DCSpecial Reporting on:• Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection• Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection• Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations• All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV• Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in DifficuIt-to-Treat HCV Infection• Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNAPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDWeill Cornell Medical CollegeNew York, New York.特别会议回顾版：2013年肝脏会议丙型肝炎病毒感染治疗进展：美国肝病研究协会第64届年会，2013年11月1日至5日，华盛顿特区。特别报道：• 西米普明联合索非布韦，加或不加利巴韦林，在基因1型丙型肝炎病毒感染中产生高持续病毒学应答率；• 新型无干扰素和利巴韦林方案在丙型肝炎病毒基因1b型感染中导致超过90%的12周持续病毒学应答率；• 研究证实辅助性西米普明在难治性丙型肝炎病毒基因1型亚群中的疗效；• 索非布韦联合利巴韦林的全口服疗法在丙型肝炎病毒和人类免疫缺陷病毒合并感染患者中产生高持续病毒学应答率；• 法达普明联合聚乙二醇干扰素和利巴韦林在难治性丙型肝炎病毒感染中显示出高疗效；• 每日一次索非布韦/雷迪帕韦组合使丙型肝炎病毒RNA迅速下降。 PLUS会议摘要及专家评论，作者：医学博士艾拉·M·雅各布森，威尔康奈尔医学院，纽约，纽约。
Gastroenterol Hepatol (N Y). 2014 Jan;10(1 Suppl 1):1-19.
2
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.特别会议回顾版：2014年欧洲肝脏研究协会第49届年会——丙型肝炎病毒感染治疗进展•2014年4月9日至13日•英国伦敦 特别报道： • SAPPHIRE II：ABT - 450/R/ABT - 267、ABT - 333与利巴韦林组成的不含干扰素的12周方案用于治疗经验丰富的丙型肝炎病毒1型感染成人的3期安慰剂对照研究 • 索磷布韦/来迪帕司韦全口服固定剂量联合用药（含或不含利巴韦林）治疗初治1型丙型肝炎病毒感染患者12周或24周：3期ION - 1研究 • PEARL - III：ABT - 450/R/267 + ABT - 333治疗12周使419例初治丙型肝炎病毒1b型感染成人（无论是否使用利巴韦林）的持续病毒学应答率超过99% • 2期研究M12 - 999结果：ABT - 450/R/ABT - 267 + ABT - 333 + 利巴韦林不含干扰素方案用于肝移植受者复发性丙型肝炎病毒1型感染 • 索磷布韦和利巴韦林治疗伴或不伴失代偿的肝硬化和门静脉高压的慢性丙型肝炎：早期病毒学应答和安全性 • 达卡他韦和阿舒瑞韦全口服双联疗法治疗丙型肝炎病毒1b型感染患者：3期研究结果 • 索磷布韦/来迪帕司韦固定剂量联合用药在包括3型患者、失代偿1型患者和有索磷布韦治疗史的1型患者等难治人群中安全有效 • 索磷布韦和利巴韦林治疗肝移植后复发性丙型肝炎感染：一项前瞻性多中心研究结果 加会议摘要总结及专家评论： 医学博士史蒂文·L·弗拉姆（Steven L. Flamm） 西北大学费恩伯格医学院肝脏移植项目主任 医学与外科学教授 伊利诺伊州芝加哥市
Gastroenterol Hepatol (N Y). 2014 Jun;10(6 Suppl 2):1-19.
3
A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • Boston, MassachusettsSpecial Reporting on:• Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO Network• Safety and Efficacy of New DAA-Based Therapy for Hepatitis C Post-Transplant: Interval Results From the HCV-TARGET Longitudinal, Observational Study• Efficacy and Safety of MK-5172 and MK-8742 ± Ribavirin in Hepatitis C Genotype 1 Infected Patients With Cirrhosis or Previous Null Response: Final Results of the C-WORTHY Study (Parts A & B)• Safety and Efficacy of Sofosbuvir in Combination With Simeprevir + Ribavirin in Patients With Genotype 1: Interim Results of a Prospective, Observational Study• All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/BMS-791325, ± Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR-12 Results• TURQUOISE-II: Regimens of ABT-450/R/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients With Cirrhosis, Regardless of Baseline CharacteristicsPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDChief of the Division of Gastroenterology and HepatologyVincent Astor Distinguished Professor of MedicineWeill Cornell Medical CollegeAttending PhysicianNewYork-Presbyterian HospitalNew York, New York.特别会议回顾版：2014年肝脏会议丙型肝炎病毒治疗亮点：2014年肝脏会议精选报告回顾，2014年11月7日至11日，马萨诸塞州波士顿。特别报道：•TRIO网络中基于索非布韦和西米普明的治疗方案评估；•基于新型直接抗病毒药物的丙型肝炎移植后治疗的安全性和有效性：HCV-TARGET纵向观察性研究的中期结果；•MK-5172和MK-8742±利巴韦林在丙型肝炎基因1型感染的肝硬化患者或既往无应答患者中的疗效和安全性：C-WORTHY研究（A和B部分）的最终结果；•索非布韦联合西米普明+利巴韦林在基因1型患者中的安全性和有效性：一项前瞻性观察性研究的中期结果；•达卡他韦/阿舒瑞韦/BMS-791325全口服固定剂量联合治疗，±利巴韦林，用于慢性丙型肝炎基因1型感染和代偿性肝硬化患者：UNITY-2 3期SVR-12结果；•TURQUOISE-II：ABT-450/R/奥比他韦和达沙布韦联合利巴韦林方案在丙型肝炎基因1型感染的肝硬化患者中实现了高SVR12率，无论基线特征如何。另外还有会议摘要及专家评论：医学博士 Ira M. Jacobson，胃肠病学和肝病科主任，威尔康奈尔医学院医学Vincent Astor杰出教授，纽约长老会医院主治医师，纽约，纽约。
Gastroenterol Hepatol (N Y). 2014 Dec;10(12 Suppl 6):1-19.
4
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 • Amsterdam, The NetherlandsSpecial Reporting on:• Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection• Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients• Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations• Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir• Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York.一期特别会议回顾版：2013年欧洲肝脏研究协会（EASL）第48届年会中丙型肝炎病毒感染治疗的进展 2013年4月24 - 28日 • 荷兰阿姆斯特丹 专题报道： • 西米普明联合聚乙二醇干扰素/利巴韦林治疗初治基因1型丙型肝炎病毒感染患者的SVR12率高 • 初治患者中，在聚乙二醇干扰素/利巴韦林中添加西米普明可更快缓解疲劳 • 索磷布韦联合利巴韦林在多个丙型肝炎病毒基因2/3型人群中显示出显著疗效 • 对于替拉普韦或博赛泼维治疗失败的基因1型患者，达克拉他韦联合索磷布韦（加或不加利巴韦林）的SVR24率达100% • 在基因1型丙型肝炎感染中，在聚乙二醇干扰素/利巴韦林中添加TG4040疫苗可提高24周时的持续病毒学应答率 另附会议摘要及专家评论： 医学博士 Ira M. Jacobson 纽约州纽约市康奈尔大学琼·桑福德·I·韦尔医学院
Gastroenterol Hepatol (N Y). 2013 Jun;9(6 Suppl 3):1-18.
5
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting: The Annual Meeting of the European Association for the Study of the Liver • April 13-17, 2016 • Barcelona, Spain• Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) Are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The HepNet Acute HCV IV Study• Treatment of Hepatitis C Virus in Patients With Advanced Cirrhosis: Always Justified? Analysis of the HEPA-C Registry• High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 in Previously Treated Patients With HCV Genotypes 1 Through 6• Prevalence and Impact of Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis• Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study• 100% SVR12 With ABT-493 and ABT-530 With or Without Ribavirin in Treatment-Naive HCV Genotype 3-Infected Patients With CirrhosisChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.一期特别会议回顾版：2016年欧洲肝脏研究学会会议上丙型肝炎病毒感染治疗进展：欧洲肝脏研究学会年会 • 2016年4月13 - 17日 • 西班牙巴塞罗那 • 索磷布韦/维帕他韦六周疗程足以治疗急性丙型肝炎病毒1型单一感染：HepNet急性丙型肝炎病毒IV研究 • 晚期肝硬化患者的丙型肝炎病毒治疗：是否始终合理？HEPA - C注册研究分析 • 索磷布韦/维帕他韦联合GS - 9857对既往接受治疗的1至6型丙型肝炎病毒患者的高效性 • 基线耐药相关变异（RAV）对来迪派韦/索磷布韦或西米普明/索磷布韦抗1型丙型肝炎病毒感染疗效的影响及流行情况：HCV - TARGET中期分析 • 索磷布韦/维帕他韦治疗丙型肝炎病毒和HIV - 1合并感染患者12周：ASTRAL - 5研究 • 初治的丙型肝炎病毒3型感染肝硬化患者使用ABT - 493和ABT - 530联合或不联合利巴韦林治疗，持续病毒学应答率达100% 肝脏移植项目主任 医学与外科学教授 西北大学费恩伯格医学院 伊利诺伊州芝加哥
Gastroenterol Hepatol (N Y). 2016 Jun;12(6 Suppl 2):1-22.
6
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.特别会议回顾版：2015年欧洲肝脏研究学会（EASL）第50届年会丙肝病毒感染治疗进展•2015年4月22 - 26日•奥地利维也纳特别报道：• 达卡他韦、索磷布韦和利巴韦林联合治疗晚期肝硬化或移植后复发丙肝患者：3期ALLY - 1研究• 格卡瑞韦和艾尔巴韦治疗Child - Pugh B级肝硬化的丙肝基因1型感染患者的疗效和安全性（C - SALT A部分）• 来迪派韦/索磷布韦联合利巴韦林治疗失代偿期及肝移植后丙肝感染患者安全有效：前瞻性SOLAR 2试验初步结果• 基于来迪派韦/索磷布韦方案治疗8周或12周失败的患者采用来迪派韦/索磷布韦再治疗24周• 索磷布韦 + 聚乙二醇干扰素/利巴韦林治疗12周与索磷布韦 + 利巴韦林治疗16周或24周用于基因3型丙肝感染患者及有治疗经验的基因2型丙肝肝硬化患者：BOSON研究• 达卡他韦 - 索磷布韦联合治疗法国观察性队列ANRS CO22 HEPATHER中丙肝基因1型单感染患者的安全性和有效性• C - SWIFT：格卡瑞韦/艾尔巴韦 + 索磷布韦治疗初治的基因1型丙肝病毒感染的肝硬化和非肝硬化患者4、6或8周，以及基因3型感染患者8或12周加会议摘要及专家评论作者：医学博士史蒂文·L·弗拉姆西北大学费恩伯格医学院肝脏移植项目主任医学与外科学教授伊利诺伊州芝加哥市
Gastroenterol Hepatol (N Y). 2015 Jun;11(6 Suppl 3):1-23.
7
A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DC• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)Chief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.一期特别会议回顾版：2017年美国肝病研究学会肝脏会议丙肝病毒研究亮点：2017年美国肝病研究学会肝脏会议部分报告回顾 • 2017年10月20 - 24日 • 华盛顿特区• 格卡瑞韦/哌柏瑞韦治疗慢性1 - 6型丙肝病毒感染合并代偿期肝硬化成人患者的疗效、安全性及药代动力学：一项综合分析• 接受阿片类激动剂治疗的参与者在接受艾尔巴韦/格拉瑞韦治疗后丙肝病毒再感染及注射风险行为：CO - STAR B部分• 格卡瑞韦/哌柏瑞韦治疗初治慢性丙肝基因3型患者8周或12周的疗效与安全性：一项2/3期综合分析• NS5A抑制剂经治的丙肝病毒感染患者使用索磷布韦/维帕他韦/伏西瑞韦治疗12周：3期POLARIS - 1研究中延迟治疗组的结果• 丙肝病毒感染患者对泛基因型格卡瑞韦/哌柏瑞韦治疗的依从性及SVR12：2/3期临床试验项目的综合分析• C - BREEZE 1和2研究：鲁扎斯韦联合乌普瑞司他韦治疗慢性丙肝病毒基因1、2、3、4或6型感染成人患者12周的疗效与安全性100% SVR率，使用来迪派韦/索磷布韦治疗8周，用于感染艾滋病毒的急性丙肝男性患者：SWIFT - C试验（不含干扰素的含索磷布韦方案治疗艾滋病毒1型感染个体的急性丙肝）结果肝病科主任大学移植中心医学临床教授德克萨斯大学健康科学中心圣安东尼奥分校德克萨斯州圣安东尼奥
Gastroenterol Hepatol (N Y). 2017 Dec;13(12 Suppl 5):1-24.
8
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012: The 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9-13, 2012 • Boston, MassachusettsSpecial Reporting on:• Timing and Magnitude of Ribavirin Dose Reduction Do Not Impact SVR Rates with Boceprevir Plus Peginterferon α and Ribavirin• A 12-Week Interferon-Free Treatment Regimen with ABT-450/r, ABT-267, ABT-333, and Ribavirin Achieves High SVR12 Rates• High Rate of SVR with the All-Oral Combination of Daclatasvir Plus Sofosbuvir with or without Ribavirin• An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir, Asunaprevir, and BMS-791325 Achieved High SVR4 RatesPLUS Meeting Abstract Summaries With Expert Commentary by: Fred Poordad, MDUniversity of San Antonio Health Science CenterSan Antonio, Texas.一期特别会议回顾版：2012年美国肝病研究学会（AASLD）第63届年会丙型肝炎病毒感染治疗进展2012年11月9日至13日•马萨诸塞州波士顿特别报道：• 利巴韦林剂量减少的时间和幅度不影响波西普韦联合聚乙二醇干扰素α及利巴韦林的持续病毒学应答率（SVR）• 采用ABT - 450/r、ABT - 267、ABT - 333和利巴韦林的12周无干扰素治疗方案可实现高SVR12率• 达卡他韦联合索磷布韦加或不加利巴韦林的全口服联合方案具有高SVR率• 达卡他韦、阿舒瑞韦和BMS - 791325的无干扰素、无利巴韦林12周方案实现了高SVR4率另附会议摘要及专家评论作者：医学博士弗雷德·普尔达德德克萨斯大学圣安东尼奥健康科学中心德克萨斯州圣安东尼奥
Gastroenterol Hepatol (N Y). 2013 Jan;9(1 Suppl 1):1-20.
9
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).来迪派韦索磷布韦联合或不联合利巴韦林治疗对既往蛋白酶抑制剂治疗无应答的 HCV 基因 1 型感染合并肝硬化患者：一项随机、双盲、II 期临床试验（SIRIUS）
Lancet Infect Dis. 2015 Apr;15(4):397-404. doi: 10.1016/S1473-3099(15)70050-2. Epub 2015 Mar 13.
10
Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.在新型直接抗病毒药物（DAA）治疗方案中添加利巴韦林，对丙型肝炎病毒1型感染者的持续病毒学应答率无影响：来自ERCHIVES的结果。
Aliment Pharmacol Ther. 2016 Oct;44(7):728-37. doi: 10.1111/apt.13748. Epub 2016 Jul 26.

引用本文的文献

1
Peginterferon and Entecavir Combination Therapy Improves Outcome of Non-Early Response Hepatitis B e Antigen-Positive Patients.聚乙二醇干扰素与恩替卡韦联合治疗改善乙肝e抗原阳性非早期应答患者的预后。
Open Forum Infect Dis. 2020 Sep 30;7(11):ofaa462. doi: 10.1093/ofid/ofaa462. eCollection 2020 Nov.
2
A Synthesis of Hepatitis C prevalence estimates in Sub-Saharan Africa: 2000-2013.撒哈拉以南非洲地区丙型肝炎患病率估计值的综合分析：2000 - 2013年
BMC Infect Dis. 2016 Jun 13;16:283. doi: 10.1186/s12879-016-1584-1.
3
The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis.肥沃新月地带丙型肝炎病毒的流行病学：系统评价与荟萃分析
PLoS One. 2015 Aug 21;10(8):e0135281. doi: 10.1371/journal.pone.0135281. eCollection 2015.
4
The genetics of hepatitis C virus underlie its ability to escape humoral immunity.丙型肝炎病毒的遗传学特征是其能够逃避免疫体液免疫的基础。
J Clin Invest. 2015 Jan;125(1):97-8. doi: 10.1172/JCI79424. Epub 2014 Dec 15.

本文引用的文献

1
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.索磷布韦联合利巴韦林治疗治疗特征不佳的丙型肝炎 1 型患者：一项随机临床试验。
JAMA. 2013 Aug 28;310(8):804-11. doi: 10.1001/jama.2013.109309.
2
Sofosbuvir for previously untreated chronic hepatitis C infection.索磷布韦片治疗未经治疗的慢性丙型肝炎感染。
N Engl J Med. 2013 May 16;368(20):1878-87. doi: 10.1056/NEJMoa1214853. Epub 2013 Apr 23.
3
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.索磷布韦用于无治疗选择的 2 或 3 型丙型肝炎病毒感染患者。
N Engl J Med. 2013 May 16;368(20):1867-77. doi: 10.1056/NEJMoa1214854. Epub 2013 Apr 23.
4
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).丙型肝炎病毒 NS3 蛋白酶抑制剂asunaprevir（BMS-650032）的临床前特征和鉴定。
Antimicrob Agents Chemother. 2012 Oct;56(10):5387-96. doi: 10.1128/AAC.01186-12. Epub 2012 Aug 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验